Boston Tech
AbbVie Bought Apogee for $10.9 Billion Because Waltham Made Eczema Dosing Less Annoying
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.
Boston Tech
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.
Boston Tech
Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.